Definium Therapeutics (NASDAQ: DFTX) recently received a number of ratings updates from brokerages and research firms: 9/15/2026 – Definium Therapeutics was given a new $78.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock. 9/15/2026 – Definium Therapeutics had its “buy” rating reaffirmed by UBS Group AG. They […]

Williams Companies (NYSE: WMB) recently received a number of ratings updates from brokerages and research firms: 9/22/2026 – Williams Companies is now covered by Capital One Financial Corporation. They set an “overweight” rating and a $92.00 price target on the stock. 9/22/2026 – Williams Companies is now covered by Melius Research. They set a “buy” […]

Several brokerages have updated their recommendations and price targets on shares of Vale (NYSE: VALE) in the last few weeks: 9/16/2026 – Vale had its price target raised by Royal Bank Of Canada from $15.00 to $16.00. They now have a “sector perform” rating on the stock. 9/9/2026 – Vale had its price target raised […]

A number of research firms have changed their ratings and price targets for Flywire (NASDAQ: FLYW): 9/17/2026 – Flywire had its “neutral” rating reaffirmed by UBS Group AG. 9/10/2026 – Flywire had its “buy” rating reaffirmed by BTIG Research. 9/1/2026 – Flywire was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”. 8/31/2026 – […]

Several analysts have recently updated their ratings and price targets for Postal Realty Trust (NYSE: PSTL): 9/14/2026 – Postal Realty Trust was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”. 9/14/2026 – Postal Realty Trust had its price target raised by BMO Capital Markets from $28.00 to $29.00. They now have an “outperform” […]

A number of research firms have changed their ratings and price targets for Bloom Energy (NYSE: BE): 9/14/2026 – Bloom Energy had its price target raised by Mizuho from $242.00 to $351.00. They now have an “outperform” rating on the stock. 9/7/2026 – Bloom Energy had its “buy” rating reaffirmed by UBS Group AG. They […]

A number of research firms have changed their ratings and price targets for Attovia Therapeutics (NASDAQ: ATTO): 9/4/2026 – Attovia Therapeutics was upgraded by Zacks Research to “hold”. 8/31/2026 – Attovia Therapeutics is now covered by Lifesci Capital. They set an “outperform” rating and a $45.00 price target on the stock. 8/31/2026 – Attovia Therapeutics […]